unit_conversion

TL3 Regular · Ljubljana, SI

Wrote most of the reconstitution worked examples. If you show me your arithmetic I will check it.

Joined 28 January 2025 · last posted 3d · groups: wiki-editors

134 posts, newest first. Showing up to 150.

What to bring: records that a clinician can actually use — a second dataset Replied, post #76 · Clinical › Prescriber conversations · 25 Jul 2026 · 3 likes I had written a reply contradicting post #74 and deleted it. Here is what survived. A question phrased as "what would you want to see before considering X" is…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #104 · Access › International · 23 Jul 2026 · 0 likes Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page. Worth checking…
Restarting after a long gap: what the labelling implies Replied, post #35 · Practice › Dosing & titration · 20 Jul 2026 · 30 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
Packaging that arrived damaged: documenting it properly Replied, post #45 · Sourcing › Logistics · 19 Jul 2026 · 1 like On post #43 — agreed on the reasoning, with one qualification. Anyone deciding whether a delay is a problem should ask what would change if they waited another week.…
Follow-up: Reading an interaction checker output critically Replied, post #50 · Practice › Interactions · 16 Jul 2026 · 0 likes Agreed on all of that, and I have nothing to add to it.
Follow-up: Signs of dehydration worth acting on Replied, post #27 · Safety › Adverse events · 16 Jul 2026 · 13 likes Speaking only to Signs of dehydration worth acting as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread…
Follow-up: How compounding permissions changed when supply normalised Replied, post #22 · Sourcing › Regulatory · 14 Jul 2026 · 4 likes Distinguishing three things in the compounding permissions discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the…
Why we ask for units every single time, with three examples of what goes wrong Replied, post #120 · Start Here › How to Ask · 12 Jul 2026 · 7 likes Everything in post #118 holds. The case it does not cover is the one I have. A photograph of a vial is rarely useful and a photograph of a document usually is. Redact…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #55 · Compounds › Retatrutide · 12 Jul 2026 · 29 likes Noted, and I have changed what I was going to do on the strength of it.
A pooled estimate that changed when one trial was added Replied, post #21 · Evidence › Meta-analyses · 10 Jul 2026 · 21 likes On post #19 — agreed on the reasoning, with one qualification. Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size…
Tracking intake honestly when appetite is absent Replied, post #90 · Nutrition & Training › Protein & intake · 8 Jul 2026 · 0 likes Worth separating two things that post #89 runs together. I would be cautious about generalising from the tracking intake example above. It is a good example. It is one…
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #113 · Evidence › Journal club · 7 Jul 2026 · 2 likes That is a cleaner way of putting what I was circling around.
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #54 · Analytics › Impurities & related substances · 7 Jul 2026 · 0 likes Scavengers and cleavage-cocktail residues can persist and appear as small early-eluting peaks. They are process-related rather than sequence-related, which is a useful…
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #68 · Analytics › Home & field testing · 6 Jul 2026 · 6 likes Post #66 describes the usual case. This is about the unusual one. I disagree with the framing of Lateral-flow and colorimetric approaches above, and I think it is a…
Selection into a registry and what it does to the estimate — a second dataset Replied, post #8 · Evidence › Study critique · 5 Jul 2026 · 0 likes A criticism that would apply equally to every trial in the field is worth stating once and is not a reason to discount a particular paper.
Constipation management, with a dietitian's contribution Replied, post #88 · Practice › Side effects · 5 Jul 2026 · 0 likes Marking my uncertainty on constipation management explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it…
Submitting a sample: the process end to end Replied, post #56 · Sourcing › Independent verification · 3 Jul 2026 · 5 likes What I would tell a new member reading about submitting a sample for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Racemisation and why it is invisible to a mass measurement Replied, post #125 · Analytics › Impurities & related substances · 15 Jun 2026 · 5 likes Racemisation produces a diastereomer that is mass-identical and chromatographically resolvable only on a method chosen for the purpose. Standard reversed-phase…
NHS criteria and how they are applied in practice Replied, post #2 · Regional › UK & Ireland · 12 Jun 2026 · 26 likes Thank you for taking the time. That was more work than a reply usually is.
Transporting a vial for a weekend away — a second dataset Replied, post #77 · Practice › Storage & stability · 9 Jun 2026 · 25 likes Adding a data point of agreement rather than a data point.
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #88 · Practice › Side effects · 2 Jun 2026 · 0 likes Marking my place. If it changes for me I will come back and say so.
Transporting a vial for a weekend away — a second dataset Replied, post #68 · Practice › Storage & stability · 31 May 2026 · 11 likes A request rather than an answer: could whoever has the primary source for Transporting a vial post it? I have seen the claim three times this month and each version had…
Why fasting instructions for oral semaglutide are not optional advice Replied, post #17 · Compounds › Oral incretins · 27 May 2026 · 0 likes I will take the caveat as seriously as the claim, which is the point of putting it there.
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #26 · Analytics › Home & field testing · 27 May 2026 · 0 likes Confirming post #23 from a second method, which matters more than confirming it from a second person. Reagent shelf life is a real constraint on kits and is frequently…
Fixed versus detachable needles: the trade-offs — does this still hold? Replied, post #5 · Devices › Syringes & needles · 27 May 2026 · 17 likes Needle length for subcutaneous delivery is a question about tissue depth and injection angle together. Short needles at ninety degrees and longer ones at an angle reach…
Research-use-only status: what it means legally and practically Replied, post #44 · Compounds › Other compounds · 18 May 2026 · 21 likes Post #42 answers the question as asked. The question underneath it is different. An observation about research-use-only status that I cannot explain and am posting…
A site rotation scheme that is easy enough to actually follow Replied, post #65 · Practice › Administration · 17 May 2026 · 0 likes One more thing on site rotation scheme that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the…
Peak-to-trough ratio at steady state for a weekly agent — the long version Replied, post #5 · Pharmacology › Pharmacokinetics · 16 May 2026 · 0 likes Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that,…
Pinch or no pinch, and how needle length changes the answer — the long version Replied, post #59 · Practice › Administration · 15 May 2026 · 31 likes I have three months of notes on Pinch and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion…
[2026 update] Regional warehouse stock versus direct despatch Replied, post #60 · Sourcing › Logistics · 4 May 2026 · 0 likes Adding a small correction to the Regional warehouse stock versus direct summary above rather than a disagreement with it. The substance holds; one of the figures is out…
The "under review" status pill and when a moderator applies it Replied, post #92 · Evidence › Preprints · 24 Apr 2026 · 14 likes If you cite a preprint in a maintained document here, the convention is to label it in the sentence and to note the check date. The document review will catch the update.
Sample handling between despatch and injection Replied, post #62 · Analytics › Method validation · 23 Apr 2026 · 6 likes Offering a way to settle sample handling between despatch rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the…
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #6 · Analytics › Home & field testing · 21 Apr 2026 · 12 likes Useful. I have added it to my own notes with the date on it.
Sample handling between despatch and injection Replied, post #53 · Analytics › Method validation · 20 Apr 2026 · 0 likes This follows post #50 rather than contradicting it. Sample handling between despatch looks different depending on whether you are reading the primary literature or the…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #149 · Access › Pricing · 17 Apr 2026 · 1 like This follows post #147 rather than contradicting it. The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion. A partial…
Transporting a vial for a weekend away — a second dataset Replied, post #28 · Practice › Storage & stability · 14 Apr 2026 · 10 likes Light protection is easy and cheap. The original carton exists for a reason and a vial stored in it is protected without anybody having to think about it again.
The "under review" status pill and when a moderator applies it Replied, post #71 · Evidence › Preprints · 13 Apr 2026 · 26 likes Author track record is a weak signal and it is a signal. A group that has published carefully for years is a different prior from an unknown one. I have seen it go both…
[2026 update] Composite endpoints and the component doing the work Replied, post #68 · Evidence › Trials · 13 Apr 2026 · 9 likes Two claims get bundled together under Composite endpoints and they need separating. The descriptive one — this is what was observed — is usually well supported. The…
Open-label extensions: what survives and what does not Replied, post #4 · Evidence › Trials · 5 Apr 2026 · 14 likes Post #3 put the caveat in the right place and I want to underline it. An open-label trial is not worthless and its subjective endpoints deserve more scepticism than its…
Revisiting: Drawing up with one needle and injecting with another Replied, post #35 · Practice › Administration · 4 Apr 2026 · 3 likes Alcohol swabbing and letting the site dry is the whole of the preparation for a subcutaneous injection into intact skin. Injecting before it dries is what stings.…
Journal club: SURMOUNT-4 and continuation versus withdrawal Replied, post #21 · Evidence › Journal club · 3 Apr 2026 · 30 likes I had written a reply contradicting post #19 and deleted it. Here is what survived. The baseline characteristics table is the single most useful page for the questions…
A site rotation scheme that is easy enough to actually follow Replied, post #32 · Practice › Administration · 2 Apr 2026 · 0 likes Adding a reference point for site rotation scheme. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted…
Personal import allowances, compared — a second dataset Replied, post #96 · Access › International · 2 Apr 2026 · 5 likes Post #94 put the caveat in the right place and I want to underline it. I would call the community position on Personal import allowances likely rather than established,…
Insomnia at a dose step: reported experiences — the long version Replied, post #6 · marked as the solution · Wellbeing › Sleep · 27 Mar 2026 · 8 likes Post #5 is the version of this I will quote in future. One addition. The most useful reply I ever got about Insomnia was a request to state my units. It sounds like…
Reconciling a label claim with a content assay Replied, post #7 · Analytics › COA interpretation · 15 Mar 2026 · 18 likes Purity and content are different measurements: purity tells you what proportion of the detected material is the intended species. Content tells you how much of the…
Contributing data without breaching anyone's privacy Replied, post #72 · Data & Tools › Datasets · 6 Mar 2026 · 11 likes Helpful, and easy to find again, which is half of what a good reply is.
Reading an interaction checker output critically Replied, post #133 · Practice › Interactions · 1 Mar 2026 · 19 likes Alcohol is not contraindicated in the labelling and it does irritate a stomach that is already emptying slowly. There is no published interaction study, and the…
Revisiting: Maintainer handover: how it works Replied, post #5 · marked as the solution · Meta › Wiki maintenance · 18 Feb 2026 · 7 likes Authority: if you think a page needs input from someone with specific expertise, suggesting that person helps the maintainer recruit contributors. Adding a source would…
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #6 · Practice › Dosing & titration · 14 Feb 2026 · 4 likes Confirming post #5 from a second method, which matters more than confirming it from a second person. Dose equivalence between different incretin analogues is a weak…
Specification in the result column: why that is a meaningful error Replied, post #116 · Analytics › COA interpretation · 3 Feb 2026 · 0 likes Everything in post #114 holds. The case it does not cover is the one I have. A chromatogram supplied as a small image is legible for peak shape and not for baseline…
Heterogeneity as information rather than as a nuisance Replied, post #87 · Evidence › Meta-analyses · 2 Feb 2026 · 6 likes The arithmetic in post #84 is right; the assumption feeding it is the part to check. Pooled estimates and heterogeneity: when trials differ in population, duration, or…
Whether protein timing matters at a large deficit Replied, post #21 · Nutrition & Training › Protein & intake · 31 Jan 2026 · 0 likes Picking up post #18: that is the part I would want checked first. Liquid versus solid: protein in liquid form (shakes) is easier to consume in volume but might not be…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #61 · Sourcing › Red flags · 23 Jan 2026 · 10 likes I had written a reply contradicting post #59 and deleted it. Here is what survived. Rapid supplier turnover: a supplier that changes corporate structure, domain name,…
Muscle cramps: the ordinary causes before the exotic ones Replied, post #38 · Practice › Side effects · 16 Jan 2026 · 11 likes Muscle cramps: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know…
Preprint servers and what screening they do Replied, post #21 · Evidence › Preprints · 11 Jan 2026 · 22 likes That matches what I have seen, for whatever a single anecdote is worth.
Pre-registering a personal experiment, seriously — a second dataset Replied, post #17 · Research Methods › N-of-1 designs · 4 Jan 2026 · 0 likes Nothing to add, except that this is the answer I would give if asked.
Why "add 2 mL" is not an instruction Replied, post #24 · Practice › Reconstitution · 2 Jan 2026 · 6 likes This follows post #23 rather than contradicting it. Preservative effectiveness is tested against a defined microbial challenge under defined conditions. It is not a…
Vomiting: when it is expected and when it is a reason to stop Replied, post #51 · Practice › Side effects · 28 Dec 2025 · 0 likes Dehydration is the mechanism behind more of the secondary complaints here than people expect. Reduced intake plus vomiting plus a warm week is a straightforward path to…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #14 · Sourcing › Independent verification · 19 Dec 2025 · 25 likes I read post #13 twice before replying, because I had assumed the opposite. VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than…
Tracking a preprint to publication: a worked example Replied, post #2 · Evidence › Preprints · 28 Nov 2025 · 0 likes Retractions and corrections do not propagate well from preprint servers. A citation that was fine when made can quietly become wrong.
Publishing an inconvenient result: a case study — the long version Replied, post #42 · Sourcing › Independent verification · 19 Nov 2025 · 1 like Post #39 is right about the mechanism and I think understates the practical bit. It does not extend to lots nobody has seen, it is not a recommendation, and it says…
Interpreting a result that disagrees with the supplier's certificate Replied, post #16 · Sourcing › Independent verification · 18 Nov 2025 · 5 likes Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies…
Cost per delivered dose, which is the number that matters Replied, post #22 · Access › Pricing · 15 Nov 2025 · 20 likes Useful. I had the fact and not the reason, which turns out to be the important half.
Angle of injection and whether 90 degrees is always right Replied, post #49 · Practice › Administration · 12 Nov 2025 · 15 likes Adding the measurement that post #46 says would settle it. Something worth flagging about angle of injection: the strongest-sounding claims in this thread are the ones…
How to read a forest plot, properly, from scratch Replied, post #53 · Evidence › Trials · 10 Nov 2025 · 0 likes Adding the measurement that post #52 says would settle it. A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #13 · Pharmacology › Pharmacokinetics · 3 Nov 2025 · 28 likes Adding a note of thanks rather than an opinion. I did not know most of that.
Where to report an adverse event officially, by region — a second dataset Replied, post #85 · Safety › Adverse events · 2 Nov 2025 · 1 like Reporting an adverse event to the national reporting scheme is possible for anybody and does not require a clinician. Those schemes exist to catch what trials could not.
What a purity-only report leaves out Replied, post #64 · Sourcing › Independent verification · 28 Oct 2025 · 33 likes Trying to state the purity-only position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
Where to report an adverse event officially, by region — a second dataset Replied, post #64 · Safety › Adverse events · 28 Oct 2025 · 0 likes Interactions with other medicines are a common contributor to events reported here, which is why the full list matters in any report.
[2026 update] A single out-of-range value on an otherwise normal panel Replied, post #18 · Clinical › Bloodwork · 27 Oct 2025 · 6 likes The bit of single out-of-range value that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the…
Why oral semaglutide needs an absorption enhancer at all Replied, post #44 · Compounds › Oral incretins · 25 Oct 2025 · 2 likes That is a cleaner way of putting what I was circling around.
An orphaned page with no inbound links — the long version Replied, post #13 · Meta › Wiki maintenance · 10 Oct 2025 · 1 like Agreed on orphaned page, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and…
"Greater than or equal to 99%" as a specification rather than a result Replied, post #47 · Analytics › COA interpretation · 5 Oct 2025 · 0 likes That reframing is the whole thing. The facts I already had.
Reading a rodent study on a secretagogue without over-extrapolating Replied, post #52 · Compounds › Secretagogues & GH axis · 26 Sep 2025 · 2 likes I changed my mind about reading a rodent study after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the…
Specification in the result column: why that is a meaningful error Replied, post #48 · Analytics › COA interpretation · 23 Sep 2025 · 1 like A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #117 · Data & Tools › Datasets · 10 Sep 2025 · 0 likes Aggregated purity results across four is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with…
A parcel that arrived warm: a decision process, not a verdict Replied, post #15 · Practice › Storage & stability · 27 Aug 2025 · 1 like Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear.
Thyroid function tests during substantial weight change Replied, post #42 · Clinical › Bloodwork · 26 Aug 2025 · 21 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #29 · Pharmacology › Receptor biology · 19 Aug 2025 · 7 likes Receptor distribution explains the side-effect profile better than anything else. GLP-1 receptors in the gastrointestinal tract and the area postrema account for most…
What a regulator's shortage notice actually authorises — what changed since Replied, post #3 · Sourcing › Regulatory · 16 Aug 2025 · 6 likes Everything in the opening post holds. The case it does not cover is the one I have. Post-authorisation safety commitments are public and are one of the more useful…
What this community means by "a source", in practical terms Replied, post #60 · Start Here › Welcome · 5 Aug 2025 · 0 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version Replied, post #4 · Clinical › Special populations · 28 Jul 2025 · 8 likes Post #3 answers the question as asked. The question underneath it is different. The most useful contribution here is usually a citation to whichever published document…
How the vendor documentation pages are maintained, and by whom — what changed since Replied, post #28 · Sourcing › Vendor reports · 21 Jul 2025 · 0 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
Coming back to: Official shortage notices and what they authorise Replied, post #47 · Access › Shortages · 4 Jul 2025 · 0 likes Official shortage notices would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Repeatability versus intermediate precision Replied, post #47 · Analytics › Method validation · 23 Jun 2025 · 31 likes On post #46 — agreed on the reasoning, with one qualification. Distinguishing three things in the repeatability versus intermediate precision discussion that keep…
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #24 · Practice › Reconstitution · 22 Jun 2025 · 27 likes Post #21 is the version of this I will quote in future. One addition. Worth stating the null on Over-dilution before we explain it: the observation may be nothing. That…
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #148 · Compounds › Cagrilintide & amylin analogues · 19 Jun 2025 · 18 likes This settles it for me, at least until somebody posts a reason it should not.
[2026 update] An appeal that failed, and what I would do differently Replied, post #81 · Access › Insurance & coverage · 12 Jun 2025 · 24 likes Denial letters: the stated reason tells you exactly what to submit next. A denial is not final; it is a specification for an appeal. Reading the reason carefully and…
Why plausible mechanism is not evidence of effect — one year on Replied, post #4 · Compounds › Repair & healing peptides · 24 May 2025 · 0 likes The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and…
Second pass at: Designing a personal experiment that could change your mind Replied, post #22 · Research Methods › N-of-1 designs · 19 May 2025 · 0 likes Post #21 answers the question as asked. The question underneath it is different. Regression to the mean explains a great many personal experiments. People start when…
Validating a calculator against hand arithmetic — what changed since Replied, post #75 · Data & Tools › Calculators · 18 May 2025 · 9 likes Reconstitution calculator: enter vial mass, final volume target, and the calculator tells you concentration and syringe mark for a given dose. Useful for…
Coverage for the indication versus for the drug Replied, post #63 · Access › Insurance & coverage · 12 May 2025 · 28 likes Where coverage was granted, saying what the successful submission contained is one of the more useful posts on the site. It is worth stating the boring hypothesis…
DXA precision and the least significant change for lean mass — the long version Replied, post #21 · Outcomes › Body composition · 9 May 2025 · 3 likes Comparison to published data: the trials reported mean fat and lean mass changes. Individual results vary around that mean. Being above or below average is not a sign…
Follow-up: What other technical communities get right that we do not Replied, post #91 · Lounge › Off topic · 8 May 2025 · 23 likes Unserious but true: I can now identify a certificate template at a glance and I have no professional use for that skill whatsoever. Not a conclusion. A place to stand…
Follow-up: Documentation that appears only after payment Replied, post #31 · Sourcing › Red flags · 29 Apr 2025 · 3 likes A note on how Documentation gets discussed rather than on Documentation itself: the confident posts get the replies and the careful ones get ignored, and the careful…
Metformin co-administration and additive GI effects Replied, post #18 · Practice › Interactions · 27 Apr 2025 · 0 likes Post #16 and I disagree about the size of the effect, not about the direction. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular…
Publishing an inconvenient result: a case study Replied, post #12 · Sourcing › Independent verification · 25 Apr 2025 · 18 likes The arithmetic in post #11 is right; the assumption feeding it is the part to check. Publishing an inconvenient result was covered in the wiki last year and the page…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #55 · Practice › Reconstitution · 22 Apr 2025 · 22 likes A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL gives roughly 2.5 mg/mL. The arithmetic is the same; the…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #46 · Evidence › Journal club · 19 Apr 2025 · 2 likes On post #44 — agreed on the reasoning, with one qualification. Reading order that works for these sessions: registry entry, methods, baseline table, primary result,…
Retatrutide dose escalation in the published trials Replied, post #148 · Compounds › Retatrutide · 18 Apr 2025 · 7 likes The version of retatrutide dose escalation that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Publishing an inconvenient result: a case study Replied, post #4 · Sourcing › Independent verification · 2 Apr 2025 · 0 likes Verification records are dated because they expire in usefulness. A result from two years ago describes a lot from two years ago. I looked this up rather than…
Follow-up: Journal club: the retatrutide phase 2 obesity paper Replied, post #14 · Evidence › Journal club · 29 Mar 2025 · 22 likes Retatrutide phase 2 obesity paper has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Fibre intake when total intake falls, and the constipation link Replied, post #46 · Nutrition & Training › Protein & intake · 29 Mar 2025 · 0 likes Fibre: adequate fibre intake supports fullness and gut motility, both of which matter during the gastrointestinal effects of these compounds. High fibre on top of…
Counter-ion form: the field almost nobody reports — one year on Replied, post #60 · Analytics › COA interpretation · 8 Mar 2025 · 14 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #121 · Compounds › Semaglutide · 5 Mar 2025 · 30 likes Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #32 · Compounds › Tirzepatide · 4 Mar 2025 · 0 likes The thing about tirzepatide in type 2 diabetes that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a…
Biased agonism: a real phenomenon, an over-used explanation Replied, post #19 · Pharmacology › Receptor biology · 28 Feb 2025 · 0 likes I had written a reply contradicting post #17 and deleted it. Here is what survived. Glucose dependence is the property that distinguishes incretin-mediated insulin…
Coming back to: An 18-month record including the parts that went badly Replied, post #21 · Outcomes › Progress reports · 26 Feb 2025 · 0 likes What I can speak to on 18-month record is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #75 · Compounds › Semaglutide · 23 Feb 2025 · 0 likes On post #73 — agreed on the reasoning, with one qualification. Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney…
Consistent declarations and why they matter more than clever ones Replied, post #15 · Sourcing › Logistics · 10 Feb 2025 · 18 likes On consistent declarations I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is…
Second pass at: Certificates issued by the seller versus by a laboratory Replied, post #82 · Analytics › COA interpretation · 30 Jan 2025 · 3 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Why we hide unevidenced fraud accusations and log the hiding Replied, post #45 · Sourcing › Red flags · 29 Jan 2025 · 2 likes The guidelines draw that line for a practical reason as much as a fair one: reports accumulate into something useful and allegations do not. That is the version I use.…
Escalating every six weeks instead of four: what I observed over eight months Replied, post #18 · Practice › Dosing & titration · 13 Jan 2025 · 11 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #22 · Compounds › Semaglutide · 10 Jan 2025 · 9 likes On post #18 — agreed on the reasoning, with one qualification. Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical…
Follow-up: Individual participant data versus aggregate data Replied, post #18 · Evidence › Meta-analyses · 8 Jan 2025 · 2 likes Offering a way to settle Individual participant data versus aggregate rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If…
Here for the analytics and not much else — one year on Replied, post #11 · Lounge › Introductions · 1 Jan 2025 · 0 likes Same experience here, different supplier, so it is at least not unique to one of them.
Fibre intake when total intake falls, and the constipation link Replied, post #11 · Nutrition & Training › Protein & intake · 28 Dec 2024 · 1 like Eating anything at all: on substantial appetite suppression, eating enough total calories to maintain lean mass is the priority. Protein comes second to total intake. I…
Oxidation pathways for methionine and tryptophan Replied, post #4 · Analytics › Impurities & related substances · 25 Dec 2024 · 4 likes Oxidation pathways for methionine: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #88 · Compounds › Semaglutide · 24 Dec 2024 · 0 likes I had written a reply contradicting post #86 and deleted it. Here is what survived. Research-use-only semaglutide is not a licensed medicine, is not manufactured to…
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Started this topic · Compounds › Semaglutide · 12 Dec 2024 · 13 likes Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits…
Follow-up: Dead volume across syringe and needle combinations Replied, post #77 · Devices › Syringes & needles · 6 Dec 2024 · 8 likes Building on post #75 rather than restating it. Filter needles are for drawing from glass ampoules where particulate is a real risk. For a stoppered vial they add dead…
Isotope patterns and why the monoisotopic peak is not the tallest Replied, post #5 · Analytics › Mass spectrometry · 5 Dec 2024 · 16 likes Electrospray ionisation produces multiply charged ions. For a 4 kDa peptide you expect mostly 2+, 3+, and 4+ charge states. Reading an electrospray spectrum means…
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #135 · Analytics › COA interpretation · 30 Nov 2024 · 0 likes When a document puts the specification in the result column, it has told you the release criterion, not the measurement. Those are different claims and the second is…
Why "any advice?" is the least effective ending for a post Replied, post #47 · Start Here › How to Ask · 18 Nov 2024 · 25 likes Do not apologise in the first line. It costs you the space where the question should be, and nobody here thinks a question is an imposition. A guess, clearly labelled…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #32 · Evidence › Journal club · 14 Nov 2024 · 18 likes Answering the question post #30 raises rather than the one it answers. The failure mode on SURPASS-2 is boring rather than dramatic. It is almost always the step…
Time to steady state after a dose increase Replied, post #81 · Pharmacology › Pharmacokinetics · 4 Nov 2024 · 9 likes Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation…
Tracking semaglutide's approved indications across jurisdictions, dated — does this… Replied, post #5 · Compounds › Semaglutide · 30 Oct 2024 · 9 likes Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely…
Why I ask for the gradient before I discuss the number Replied, post #30 · Analytics › HPLC & UHPLC · 24 Oct 2024 · 12 likes Post #27 is right about the mechanism and I think understates the practical bit. This is why a purity figure without the underlying chromatogram is weaker evidence than…
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #15 · Evidence › Journal club · 12 Aug 2024 · 19 likes No notes. Posting so the count is not one.
Reporting a discrepancy without making an allegation Replied, post #20 · Sourcing › Vendor reports · 9 Aug 2024 · 9 likes Narrowing post #19, because the general version has more than one answer. Do not adjust a reported figure. Post what the laboratory said and put your interpretation in…
Cold packs, phase-change material, and what survives ten days Replied, post #117 · Sourcing › Logistics · 18 Jul 2024 · 0 likes Document outcomes rather than forecasting them. A forecast in this category reads as reassurance and is not one.
Journal club: FLOW and the renal composite, component by component Replied, post #67 · Evidence › Journal club · 15 Jul 2024 · 7 likes Picking up post #65: that is the part I would want checked first. The figures usually contain the finding and the text usually contains the interpretation. Separating…
Coming back to: Preparing for an appointment: one page, three questions Replied, post #15 · Clinical › Prescriber conversations · 4 Jul 2024 · 4 likes A second opinion is a normal part of medicine rather than an accusation, and asking how to obtain one is a legitimate question.
Two sessions a week versus four: what the evidence supports — a second dataset Replied, post #20 · Nutrition & Training › Resistance training · 28 Jun 2024 · 15 likes Recording sessions is what makes progression visible. Without a log, load creep and load decline both go unnoticed.